Loading...
XNASMRUS
Market cap2.91bUSD
Dec 23, Last price  
42.45USD
1D
1.43%
1Q
-10.91%
Jan 2017
101.09%
IPO
324.50%
Name

Merus NV

Chart & Performance

D1W1MN
XNAS:MRUS chart
P/E
—
P/S
66.13
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
18.29%
Rev. gr., 5y
4.09%
Revenues
44m
+5.68%
260,984944,8411,437,6922,859,57614,882,30935,973,46131,133,00029,943,00049,107,00041,586,00043,947,000
Net income
-155m
L+18.10%
000000-55,151,000-85,513,000-66,816,000-131,194,000-154,939,000
CFO
-142m
L-5.13%
000000-63,048,000-79,901,000-59,627,000-149,899,000-142,207,000
Earnings
Feb 26, 2025

Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
URL
https://merus.nl/
IPO date
May 19, 2016
Employees
164
Domiciled in
NL
Incorporated in
NL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
43,947
5.68%
41,586
-15.32%
49,107
64.00%
Cost of revenue
200,494
213,606
225,350
Unusual Expense (Income)
NOPBT
(156,547)
(172,020)
(176,243)
NOPBT Margin
Operating Taxes
3,192
959
239
Tax Rate
NOPAT
(159,739)
(172,979)
(176,482)
Net income
(154,939)
18.10%
(131,194)
96.35%
(66,816)
-21.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
225,945
57,740
264,822
BB yield
-15.92%
-8.31%
-21.55%
Debt
Debt current
1,674
1,684
1,494
Long-term debt
22,650
25,264
6,008
Deferred revenue
19,574
38,771
66,244
Other long-term liabilities
(3,365)
(1,058)
Net debt
(388,164)
(299,738)
(423,220)
Cash flow
Cash from operating activities
(142,207)
(149,899)
(59,627)
CAPEX
(3,982)
(7,639)
(870)
Cash from investing activities
(27,020)
2,802
(146,623)
Cash from financing activities
230,086
58,739
281,955
FCF
(158,396)
(190,537)
(175,742)
Balance
Cash
355,176
290,229
410,425
Long term investments
57,312
36,457
20,297
Excess cash
410,291
324,607
428,267
Stockholders' equity
(769,711)
(623,819)
(471,668)
Invested Capital
1,154,790
917,354
856,806
ROIC
ROCE
EV
Common stock shares outstanding
51,605
44,919
38,638
Price
27.50
77.76%
15.47
-51.35%
31.80
81.40%
Market cap
1,419,150
104.22%
694,898
-43.44%
1,228,702
139.58%
EV
1,030,986
395,160
805,482
EBITDA
(154,007)
(170,735)
(174,758)
EV/EBITDA
Interest
2,722
129
Interest/NOPBT